首页> 美国卫生研究院文献>other >Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive HER2-positive metastatic breast cancer

【2h】

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive HER2-positive metastatic breast cancer

机译：曲妥珠单抗联合培妥珠单抗对曲妥珠单抗不敏感的HER2阳性转移性乳腺癌患者的心脏毒性和疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo evaluate safety and efficacy of trastuzumab with pertuzumab in patients with HER2+ metastatic breast cancer (MBC) who had progressive disease on trastuzumab-based therapy.

机译：目的评估曲妥珠单抗联合帕妥珠单抗在以曲妥珠单抗为基础治疗而患有进行性疾病的HER2 +转移性乳腺癌（MBC）患者中的安全性和有效性。

著录项

期刊名称 other
作者
Chia C. Portera; Janice M. Walshe; Douglas R. Rosing; Neelima Denduluri; Arlene W. Berman; Ujala Vatas; Margarita Velarde; Catherine K. Chow; Seth M. Steinberg; Diana Nguyen; Sherry X. Yang; Sandra M. Swain;
展开▼
作者单位

展开▼
年(卷),期 -1(14),9
年度 -1
页码 2710–2716
总页数 17
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A Phase II, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxe! in Patients With Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla2期

机译：II期，随机，双盲，安慰剂对照的注册试验，用于评估帕妥珠单抗+曲妥珠单抗+多西他赛与安慰剂+曲妥珠单抗+多西他赛的疗效和安全性！未经治疗的HER2阳性转移性乳腺癌（CLEOPATRA）患者中
2. Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment [J] . J.Cortes, K.Gelmon, P.Fumoleau, European Journal of Cancer Supplements . 2008,第7期

机译：曲妥珠单抗联合培妥珠单抗治疗在曲妥珠单抗治疗期间进展的HER2阳性转移性乳腺癌患者中的有效性和安全性的第二阶段评估
3. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [J] . Yamamoto Yutaka, Iwata Hiroji, Ueno Takayuki, Japanese journal of clinical oncology. . 2018,第9期

机译：在Her2阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，曲妥珠单抗和化疗：日本乳腺癌研究组-M05珍贵研究
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results [O] . Edith A. Perez, José Manuel López-Vega, Thierry Petit, 2016

机译：长春瑞滨联合培妥珠单抗和曲妥珠单抗联合用于HER2阳性局部晚期或转移性乳腺癌患者的一线治疗的安全性和有效性：VELVET研究组1的最终结果
7. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [O] . Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, 2018

机译：在Her2-阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，先前用Pertuzumab，Trastuzumab和化疗治疗：日本乳腺癌研究组-M05珍贵研究

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive HER2-positive metastatic breast cancer

摘要

著录项

相似文献

相关主题

期刊订阅